Not Yet Recruiting PHASE2 NCT07059338
Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer
Trastuzumab in Combination With Cetuximab and Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer：A Phase II, Open-Label Trial
Sponsor: Sun Yat-sen University
Conditions
Colorectal Cancer (CRC) HER2 Positive
Interventions
Trastuzumab +Cetuximab β+Irinotecan
Updated 1 time since 2025 Last updated: Jul 7, 2025 Started: Jul 11, 2025 Primary completion: Dec 30, 2027 Completion: Dec 30, 2028
Listed as NCT07059338, this PHASE2 trial focuses on Colorectal Cancer (CRC) and HER2 Positive and remains actively recruiting participants. Sponsored by Sun Yat-sen University, it has been updated 1 time since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Sun Yat-sen University
Data source: Sun Yat-sen University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Guangzhou, China